MC2 Therapeutics aims to lead psoriasis market

Psoriasis drug Wynzora brings MC2 Therapeutics one step closer to achieving its goal of becoming world-leading within drugs applied onto skin, says MC2 Therapeutics CEO Jesper Lange.

MC2 Therapeutics CEO Jesper Lange | Photo: MC2 Therapeutics / PR

Danish pharmaceutical company MC2, which is owned by family members behind major Danish companies Danfoss and Radiometer, dreams of becoming world-leading in drugs applied to the skin. The first step towards reaching this goal includes psoriasis drug Wynzora, which has been approved by the US Food and Drug Administration and is being launched in the US, and which awaits Europe approval in summer, according to Danish newspaper Børsen.

On the European market, which is worth USD 300-400m, Spanish pharmaceutical company Almirall will take charge of Wynzora sales.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs